Eyepoint Pharmaceuticals Stock Earnings Reports

EyePoint reported steady execution in Q1 2026 while advancing DURAVYU (EYP-1901) through pivotal Phase III programs in wet AMD and DME. Key clinical updates: LUGANO and LUCIA (Phase III wet AMD) remain on track for top-line readouts beginning mid-year 2026, with all patients having reached the week-32 visit and >35% having received the third dose at week 56; independent Data Safety Monitoring Committee (DMC) previously gave two positive recommendations and a third review is scheduled. The DME Phase III trials (COMO and CAPRI) are enrolling rapidly with >1/3 of patients enrolled and full enrollment targeted in Q3 2026; top-line DME data expected H2 2027. Company emphasized DURAVYU’s differentiated multi-mechanism profile (VEGF/PDGF receptor blockade and preclinical evidence of JAK1/IL-6 inhibition) and favorable safety history across >190 patients in four completed trials. Commercial and CMC readiness progress includes hiring a Chief Commercial Officer, expansion of commercial functions, and a cGMP facility in Northbridge, MA supporting anticipated CMC submission and potential commercial supply. Financials: Q1 2026 net revenue was $0.7M (vs. $24.5M prior year, driven by prior deferred revenue recognition), operating expenses increased to $88M reflecting Phase III activity and manufacturing scale-up, net loss was $85M ($0.99/share). Cash and investments totaled $223M at March 31, 2026, with management expecting runway into Q4 2027, covering key near-term milestones. Management reiterated a derisked, non-inferiority regulatory strategy, focus on treatment burden reduction (6-month redosing), and belief that DURAVYU could be a first/ best-in-class durable retinal therapy if Phase III readouts are positive.